{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:53:10Z","timestamp":1761238390119,"version":"3.37.3"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001843","name":"SERB","doi-asserted-by":"publisher","award":["SERC\/LS-411\/2011"],"award-info":[{"award-number":["SERC\/LS-411\/2011"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013306","name":"NISER","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001502","name":"DAE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001502","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The prime objective of current work was to develop a strategy for preparation of combinational nano-formulation for reversal of drug resistance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>As a model system, doxorubicin (DOX)-resistant COLO205 cells were developed and validated. From co-treatment studies with DOX, curcumin was selected as it reversed DOX-resistance at lowest concentration. In an attempt to increase its solubility, curcumin was encapsulated into hydroxypropyl-\u03b2-cyclodextrin (HP-\u03b2-CD). Here, we propose that presence of stabilizer overcomes its low encapsulation efficiency. Thus, we evaluated curcumin encapsulation in HP-\u03b2-CD in presence of different stabilizers and organic solvents. Finally, the effect of nanocurcumin with liposomal DOX was studied for reversal of resistance in COLO205 cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>In the process encapsulation, selective optimization of organic solvent by freeze-drying was found to be appropriate among other methods. From optimization studies with different organic solvent (acetone and dichloromethane) and stabilizer [polyvinyl alcohol (PVA) and Pluronics], HP-\u03b2-CD-encapsulated curcumin prepared using acetone in PVA-stabilized dispersion increased encapsulation (60%) with size of ~40 nm. Prepared nano-curcumin reversed the DOX resistance effectively in combination with liposomal DOX.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Curcumin reversed DOX resistance in COLO205 cells at low concentration and enhanced curcumin encapsulation in HP-\u03b2-CD was noted in presence of PVA. Further, it was observed that prepared HP-\u03b2-CD-encapsulated curcumin is equi-efficacious to nano-dispersed curcumin.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jphp.12722","type":"journal-article","created":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T08:42:43Z","timestamp":1491900163000},"page":"834-843","source":"Crossref","is-referenced-by-count":17,"title":["Selection and optimization of nano-formulation of P-glycoprotein inhibitor for reversal of doxorubicin resistance in COLO205 cells"],"prefix":"10.1093","volume":"69","author":[{"given":"Tapan K","family":"Dash","sequence":"first","affiliation":[{"name":"School of Biological Sciences, National Institute of Science Education and Research (NISER, HBNI) , Khurda,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3699-7490","authenticated-orcid":false,"given":"Venkata Sai Badireenath","family":"Konkimalla","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, National Institute of Science Education and Research (NISER, HBNI) , Khurda,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,7,1]]},"reference":[{"key":"2024103012562951400_jphp12722-cit-0001","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nature14971","article-title":"A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity","volume":"525","author":"Waclaw","year":"2015","journal-title":"Nature"},{"key":"2024103012562951400_jphp12722-cit-0002","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature12624","article-title":"Tumour heterogeneity and cancer cell plasticity","volume":"501","author":"Meacham","year":"2013","journal-title":"Nature"},{"key":"2024103012562951400_jphp12722-cit-0003","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szakacs","year":"2006","journal-title":"Nat Rev Drug Discovery"},{"key":"2024103012562951400_jphp12722-cit-0004","first-page":"95","article-title":"Cellular mechanisms of multidrug resistance of tumor cells","volume":"65","author":"Stavrovskaya","year":"2000","journal-title":"Biochemistry"},{"key":"2024103012562951400_jphp12722-cit-0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.drup.2012.01.006","article-title":"The tumor microenvironment is a dominant force in multidrug resistance","volume":"15","author":"Correia","year":"2012","journal-title":"Drug Resist Updat"},{"key":"2024103012562951400_jphp12722-cit-0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2867-5-30","article-title":"ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal","volume":"5","author":"Choi","year":"2005","journal-title":"Cancer Cell Int"},{"key":"2024103012562951400_jphp12722-cit-0007","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1749-8546-5-26","article-title":"Circumvention of multi-drug resistance of cancer cells by Chinese herbal medicines","volume":"5","author":"Chai","year":"2010","journal-title":"Chin Med"},{"key":"2024103012562951400_jphp12722-cit-0008","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/138161206775201893","article-title":"Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids","volume":"12","author":"Molnar","year":"2006","journal-title":"Curr Pharm Des"},{"key":"2024103012562951400_jphp12722-cit-0009","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1043-6618(03)00158-0","article-title":"P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement","volume":"48","author":"Varma","year":"2003","journal-title":"Pharmacol Res"},{"key":"2024103012562951400_jphp12722-cit-0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.18433\/J3RC77","article-title":"Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy","volume":"12","author":"Bansal","year":"2009","journal-title":"J Pharm Pharm Sci"},{"key":"2024103012562951400_jphp12722-cit-0011","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3923\/tmr.2012.34.42","article-title":"Nanotechnology: a tool to enhance therapeutic values of natural plant products","volume":"7","author":"Kumari","year":"2012","journal-title":"Trends Med Res"},{"key":"2024103012562951400_jphp12722-cit-0012","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11095-007-9347-8","article-title":"Natural and synthetic polymers as inhibitors of drug efflux pumps","volume":"25","author":"Werle","year":"2008","journal-title":"Pharm Res"},{"key":"2024103012562951400_jphp12722-cit-0013","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1590\/S1984-82502012000300002","article-title":"Overview of P-glycoprotein inhibitors: a rational outlook","volume":"48","author":"Srivalli","year":"2012","journal-title":"Braz J Pharma Sci"},{"key":"2024103012562951400_jphp12722-cit-0014","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1368-7646(03)00082-7","article-title":"Liposome-based approaches to overcome anticancer drug resistance","volume":"6","author":"Mamot","year":"2003","journal-title":"Drug Resist Updat"},{"key":"2024103012562951400_jphp12722-cit-0015","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.drudis.2009.07.010","article-title":"Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation","volume":"14","author":"Bansal","year":"2009","journal-title":"Drug Discov Today"},{"key":"2024103012562951400_jphp12722-cit-0016","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2174\/138920009790274540","article-title":"Therapeutic nanoparticles to combat cancer drug resistance","volume":"10","author":"Hu","year":"2009","journal-title":"Curr Drug Metab"},{"key":"2024103012562951400_jphp12722-cit-0017","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1007\/s00018-009-0053-z","article-title":"Nanocarriers' entry into the cell: relevance to drug delivery","volume":"66","author":"Hillaireau","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"2024103012562951400_jphp12722-cit-0018","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ctrv.2008.04.003","article-title":"Multi-functional nanocarriers to overcome tumor drug resistance","volume":"34","author":"Jabr-Milane","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"2024103012562951400_jphp12722-cit-0019","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4155\/tde.10.13","article-title":"Nanoparticle-assisted combination therapies for effective cancer treatment","volume":"1","author":"Hu","year":"2010","journal-title":"Ther Deliv"},{"key":"2024103012562951400_jphp12722-cit-0020","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1124\/mol.65.5.1208","article-title":"Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport","volume":"65","author":"Zhang","year":"2004","journal-title":"Mol Pharmacol"},{"key":"2024103012562951400_jphp12722-cit-0021","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2174\/138920111795163887","article-title":"Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy","volume":"12","author":"Wu","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"key":"2024103012562951400_jphp12722-cit-0022","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.molstruc.2014.07.007","article-title":"Reaction between lawsone and aminophenol derivatives: synthesis, characterization, molecular structures and antiproliferative activity","volume":"1075","author":"Kathawate","year":"2014","journal-title":"J Mol Struct"},{"key":"2024103012562951400_jphp12722-cit-0023","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2024103012562951400_jphp12722-cit-0024","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-016-0614-z","article-title":"Formulation and optimization of doxorubicin and biochanin A combinational liposomes for reversal of chemoresistance","author":"Dash","year":"2016","journal-title":"AAPS PharmSciTech"},{"key":"2024103012562951400_jphp12722-cit-0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s11094-011-0661-4","article-title":"Specific features of drug encapsulation in liposomes (A review)","volume":"45","author":"Tazina","year":"2011","journal-title":"Pharm Chem J"},{"key":"2024103012562951400_jphp12722-cit-0026","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil(R)\u2013the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J Control Release"},{"key":"2024103012562951400_jphp12722-cit-0027","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1477-3155-9-3","article-title":"The use of some nanoemulsions based on aqueous propolis and lycopene extract in the skin's protective mechanisms against UVA radiation","volume":"9","author":"Butnariu","year":"2011","journal-title":"J Nanobiotechnol"},{"key":"2024103012562951400_jphp12722-cit-0028","first-page":"945","article-title":"Microencapsulation of the allelochemical compounds and study of their release from different products","volume":"8","author":"Barbat","year":"2013","journal-title":"Dig J Nanomater Biostruct"},{"key":"2024103012562951400_jphp12722-cit-0029","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2013007346","article-title":"Nanoformulations for delivery of biomolecules: focus on liposomal variants for siRNA delivery","volume":"30","author":"Dash","year":"2013","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"2024103012562951400_jphp12722-cit-0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.colsurfb.2010.03.039","article-title":"beta-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells","volume":"79","author":"Yallapu","year":"2010","journal-title":"Colloids Surf B Biointerfaces"},{"key":"2024103012562951400_jphp12722-cit-0031","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.vibspec.2012.06.008","article-title":"Encapsulation and isomerization of curcumin with cyclodextrins characterized by electronic and vibrational spectroscopy","volume":"62","author":"Lopez-Tobar","year":"2012","journal-title":"Vib Spectrosc"},{"key":"2024103012562951400_jphp12722-cit-0032","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bcp.2010.06.022","article-title":"Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake","volume":"80","author":"Yadav","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"2024103012562951400_jphp12722-cit-0033","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.colsurfb.2014.03.005","article-title":"Curcumin-cyclodextrin encapsulated chitosan nanoconjugates with enhanced solubility and cell cytotoxicity","volume":"117","author":"Popat","year":"2014","journal-title":"Colloids Surf B Biointerfaces"},{"key":"2024103012562951400_jphp12722-cit-0034","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10847-009-9651-5","article-title":"Studies of curcumin and curcuminoids XXXVI. The stoichiometry and complexation constants of cyclodextrin complexes as determined by the phase-solubility method and UV\u2013Vis titration","volume":"66","author":"Singh","year":"2009","journal-title":"J Incl Phenom Macrocycl Chem"},{"key":"2024103012562951400_jphp12722-cit-0035","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.4314\/tjpr.v13i8.4","article-title":"Curcumin-Hydroxypropyl-Cyclodextrin inclusion complex preparation methods: effect of common solvent evaporation, freeze drying, and pH shift on solubility and stability of curcumin","volume":"13","author":"Jantarat","year":"2014","journal-title":"Trop J Pharm Res"},{"key":"2024103012562951400_jphp12722-cit-0036","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2011.09.064","article-title":"Poly-\u03b5-caprolactone based formulations for drug delivery and tissue engineering: a review","volume":"158","author":"Dash","year":"2012","journal-title":"J Control Release"},{"key":"2024103012562951400_jphp12722-cit-0037","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4236\/jbnb.2013.43037","article-title":"Pharmacokinetic study of nanoparticulate curcumin: oral formulation for enhanced bioavailability","volume":"4","author":"Ravichandran","year":"2013","journal-title":"J Biomater Nanobiotechnol"},{"key":"2024103012562951400_jphp12722-cit-0038","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1208\/s12248-012-9444-4","article-title":"Highly stabilized curcumin nanoparticles tested in an in vitro blood brain barrier model and in Alzheimers disease Tg2576 mice","volume":"15","author":"Cheng","year":"2012","journal-title":"AAPS J"},{"key":"2024103012562951400_jphp12722-cit-0039","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1021\/jf104402t","article-title":"Curcumin nanoparticles: preparation, characterization, and antimicrobial study","volume":"59","author":"","year":"2011","journal-title":"J Agric Food Chem"},{"key":"2024103012562951400_jphp12722-cit-0040","doi-asserted-by":"crossref","first-page":"694","DOI":"10.6061\/clinics\/2013(05)18","article-title":"Effect of curcumin on human colon cancer multidrug resistance in vitro and in vivo","volume":"68","author":"Lu","year":"2013","journal-title":"Clinics (Sao Paulo)"},{"key":"2024103012562951400_jphp12722-cit-0041","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ijpharm.2015.09.022","article-title":"On-demand combinational delivery of curcumin and doxorubicin via a pH-labile micellar nanocarrier","volume":"495","author":"Li","year":"2015","journal-title":"Int J Pharm"},{"key":"2024103012562951400_jphp12722-cit-0042","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.biomaterials.2013.10.074","article-title":"Simultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature","volume":"35","author":"Barui","year":"2014","journal-title":"Biomaterials"},{"key":"2024103012562951400_jphp12722-cit-0043","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ijc.23097","article-title":"Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R","volume":"122","author":"Patel","year":"2008","journal-title":"Int J Cancer"},{"key":"2024103012562951400_jphp12722-cit-0044","doi-asserted-by":"crossref","first-page":"24675","DOI":"10.1038\/srep24675","article-title":"Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine\/NF-kappaB signalling pathway","volume":"6","author":"Ruiz de Porras","year":"2016","journal-title":"Sci Rep"},{"key":"2024103012562951400_jphp12722-cit-0045","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ijc.22645","article-title":"Comparison of oxaliplatin- and curcumin-mediated antiproliferative effects in colorectal cell lines","volume":"121","author":"Howells","year":"2007","journal-title":"Int J Cancer"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12722","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/69\/7\/834\/60231179\/jphp12722.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/69\/7\/834\/60231179\/jphp12722.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T18:26:50Z","timestamp":1730312810000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/69\/7\/834\/6127886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,1]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,1]]},"published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.12722","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"type":"electronic","value":"2042-7158"},{"type":"print","value":"0022-3573"}],"subject":[],"published-other":{"date-parts":[[2017,7]]},"published":{"date-parts":[[2017,7,1]]}}}